北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学公共卫生学院  > 期刊论文
学科主题: 公共卫生
题名:
Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
作者: Sun, Feng1,2; Wu, Shanshan1; Wang, Jing1; Guo, Shuxia2; Chai, Sanbao3; Yang, Zhirong1,4; Li, Lishi1,5; Zhang, Yuan1; Ji, Linong6; Zhan, Siyan1
关键词: GLP-1 receptor agonists ; lipid profiles ; network meta-analysis ; type 2 diabetes
刊名: CLINICAL THERAPEUTICS
发表日期: 2015
DOI: 10.1016/j.clinthera.2014.11.008
卷: 37, 期:1, 页:225-241
收录类别: SCI
文章类型: Review
WOS标题词: Science & Technology
类目[WOS]: Pharmacology & Pharmacy
研究领域[WOS]: Pharmacology & Pharmacy
关键词[WOS]: RANDOMIZED CLINICAL-TRIALS ; PLACEBO-CONTROLLED TRIAL ; CARDIOVASCULAR RISK ; OPEN-LABEL ; PRIMARY-PREVENTION ; INSULIN GLARGINE ; DOUBLE-BLIND ; GLYCEMIC CONTROL ; EXENATIDE TWICE ; PARALLEL-GROUP
英文摘要:

Purpose: The goal of this study was to assess the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on lipid profiles in patients with type 2 diabetes.

Methods: The MEDLINE, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched from inception through October 31, 2013. Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional antidiabetic drugs with a duration >= 8 weeks. The weighted mean difference for changes in lipid profiles was estimated by using the random effects model, and a network meta-analysis was performed to supplement direct comparisons.

Findings: Thirty-five trials with 13 treatments were included in the analysis. GLP-1 RAs decreased HDL-C with a range of -0.06 mmol/L (95% CI, -0.11 to -0.01) to -0.13 mmol/L (95% CI, -0.17 to -0.10) compared with thiazolidinediones, whereas thiazolidinediones were associated with a significant increase in HDL-C compared with placebo (0,09 mmol/L [95% CI, 0.06 to 0.12]). A significant reduction in LDL-C was detected for all GLP-1 RAs versus placebo (range, -0.08 to -0.16 mmol/L), insulin (range, -0.10 to -0.19 mmol/L), and thiazolidinediones (range, -0.16 to -0.24 mmol/L). Exenatide, liraglutide 1.8 mg once daily, and taspoglutide decreased total cholesterol with a range of -0.16 mmol/L (95% CI, -0.26 to -0.06) to -0.27 mmol/L (95% CI, -0.41 to -0.12) versus placebo and thiazolidinediones (range, -0.26 to -0.37 mmol/L). The decreased effect was more evident in exenatide long-acting release and liraglutide 1.8 mg once daily. A significant reduction in triglyceride levels was observed with liraglutide 1.8 mg once daily (-0.30 mmol/L [95% CI, -0.49 to -0.11]) and taspoglutide 20 mg once weekly (-0.17 mmol/L [95% CI, -0.31 to -0.01]) versus placebo.

Implications: GLP-1 RAs were associated with modest reductions in LDL-C, total cholesterol, and triglycerides but no significant improvement in HDL-C. Further evidence is needed to determine if improvements in lipid profiles might translate into reductions in cardiovascular outcomes. (C) 2015 Elsevier HS Journals, Inc. All rights reserved.

语种: 英语
所属项目编号: 81302508 ; 20120001110015 ; 2010JC15 ; 2009BAI82B04
项目资助者: National Natural Science Foundation of China ; Research Fund for the Doctoral Program of Higher Education ; Doctoral Fund of Corps ; National Key Technology R&amp ; D Program of China
WOS记录号: WOS:000348179100021
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/64548
Appears in Collections:北京大学公共卫生学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Columbia Univ, Grad Sch Arts & Sci, Dept Stat, New York, NY USA
2.Capital Med Univ, Dept Physiol, Beijing, Peoples R China
3.Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China
4.Shihezi Univ, Coll Med, Dept Prevent Med, Shihezi, Peoples R China
5.Shantou Univ, Coll Med, Shantou Oxford Clin Res Unit, Shantou, Guangdong, Peoples R China
6.Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, Beijing 100871, Peoples R China

Recommended Citation:
Sun, Feng,Wu, Shanshan,Wang, Jing,et al. Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis[J]. CLINICAL THERAPEUTICS,2015,37(1):225-241.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Sun, Feng]'s Articles
[Wu, Shanshan]'s Articles
[Wang, Jing]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Sun, Feng]‘s Articles
[Wu, Shanshan]‘s Articles
[Wang, Jing]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace